Nasal Spray Shows Promise as "Universal Vaccine" Against Respiratory Bugs

Stanford researchers test a new approach to priming the lungs' defenses against a wide range of viruses and bacteria.

Feb. 21, 2026 at 3:08am

Got story updates? Submit your updates here. ›

Scientists at Stanford University are testing a nasal spray that aims to put the lungs on alert against a variety of respiratory bugs, including viruses, bacteria, and even allergens. Unlike traditional vaccines that teach the immune system to recognize a specific pathogen, this "universal vaccine" appears to tune up the lung's first responder cells, known as macrophages, to be primed and ready to attack a wide range of threats.

Why it matters

If proven effective, this nasal spray could provide broad protection against respiratory illnesses, which are a leading cause of illness and death worldwide. The ability to prime the lungs' defenses against multiple threats, rather than a single pathogen, represents a potential breakthrough in vaccine technology.

The details

The Stanford researchers' approach does not teach the immune system to recognize a specific virus or bacteria the way traditional vaccines do. Instead, it appears to activate the lung's macrophages, white blood cells that act as first responders, so they are primed and ready to attack a wide range of respiratory threats, including viruses, bacteria, and even allergens like dust mites. In animal tests, the nasal spray was able to blunt reactions to dust-mite allergens in addition to protecting against respiratory infections.

  • The Stanford study was published in the journal Science on February 21, 2026.

The players

Stanford University

A prestigious research university located in California, known for its innovative work in medicine and technology.

Suresh Mittal

A vaccinologist at Purdue University who was not involved in the Stanford study, but commented on its significance.

Got photos? Submit your photos here. ›

What they’re saying

“It's an important study because they were able to dissect out how this protection is happening.”

— Suresh Mittal, Vaccinologist

What’s next

The Stanford researchers plan to continue testing the nasal spray in further animal studies and eventually move towards human clinical trials to assess its safety and efficacy.

The takeaway

This novel approach to priming the lungs' defenses against a wide range of respiratory threats, rather than targeting a specific pathogen, represents a potentially groundbreaking advancement in vaccine technology that could have major implications for public health if proven successful.